Image source: © 2025 Krish Capital Pty.Ltd

Highlights

  • HC Wainwright maintains a Neutral rating on VRNA, lifting its price target to USD 107.
  • Multiple brokerages recently shifted VRNA from buy recommendations to hold ratings.
  • Verona’s stock trades near its 52-week high following a strong Q1 earnings surprise.

Shares of Verona Pharma PLC American Depositary Share (NASDAQ: VRNA) continue to trade near record highs, with analysts offering a mixed outlook for the clinical-stage biopharmaceutical firm. HC Wainwright reiterated its “Neutral” rating on Verona in a note issued Monday, raising its price target from USD 90 to USD 107. This implies a modest potential upside of approximately 2.13% from Verona’s prior closing price of USD 104.77.

The company has seen a flurry of rating changes recently, as several brokerages tempered their previous optimism. Roth Capital, Wolfe Research, BTIG Research, Truist Financial, and TD Cowen all downgraded Verona from buy-oriented ratings to “Hold” in reports released last week. Data compiled by MarketBeat shows the stock holds an overall consensus rating of “Hold” among thirteen analysts, with a consensus price target of USD 109.

Despite the cautious sentiment, Verona’s share price has surged over the past year, climbing from a 52-week low of USD 18.51 to a recent high of USD 104.99. The company surprised markets in April when it posted quarterly earnings of USD 0.27 per share, outperforming analysts’ estimates of a USD 0.22 per share loss. Revenue reached USD 98.65 million, more than double consensus forecasts of USD 41.47 million. For the full year, analysts expect Verona to report a loss of USD 1.95 per share.

Trading data shows Verona maintains healthy liquidity metrics, with a quick ratio of 8.73 and a current ratio of 8.86. Its debt-to-equity ratio stands at 1.07. However, the company’s price-to-earnings ratio remains negative at -52.39, reflecting its pre-profit stage and ongoing development costs for its primary drug candidate, ensifentrine—a dual PDE3 and PDE4 inhibitor under investigation for respiratory conditions including COPD, asthma, and cystic fibrosis.

Recent insider activity has also drawn attention. General Counsel Andrew Fisher sold 80,000 shares in June for USD 922,400, trimming his stake by over 18%. CFO Mark Hahn sold 400,000 shares valued at roughly USD 4.56 million. In total, insiders have sold approximately USD 20 million worth of stock in the past quarter, though insiders still hold around 4.80% of the company.

Institutional interest remains solid, with hedge funds and institutional investors owning nearly 86% of the float. Notably, GAMMA Investing, Townsquare Capital, and Advisors Preferred LLC have all adjusted their stakes in recent quarters.

Overall, while Verona Pharma’s recent financial results have surpassed expectations, analysts appear cautious about near-term upside, citing valuation levels and clinical risks typical for biopharma companies still in development stages.